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Abstract
Results from a recent study investigating the metabolic effects of consuming fructose-sweetened beverages at 25% of
energy requirements for 10 wk demonstrate that a high-fructose diet induces dyslipidemia, decreases insulin sensitivity,
and increases visceral adiposity. The purpose of this review is to present aspects of the study design which may be critical
for assessment of the metabolic effects of sugar consumption. Collection of postprandial blood samples is required to
document the full effects of fructose on lipidmetabolism. Fasting triglyceride (TG) concentrations are an unreliable index of
fructose-induced dyslipidemia. Differences in the short-term (24-h) and long-term (.2wk) effects of fructose consumption
on TG and apolipoprotein-B demonstrate that acute effects can differ substantially from those occurring after sustained
fructose exposure. Investigating the effects of fructose when consumed ad libitum compared with energy-balanced diets
suggest that additive effects of fructose-induced de novo lipogenesis and positive energy balance may contribute to
dyslipidemia and decreased insulin sensitivity. Increases of intra-abdominal fat observed in subjects consuming fructose,
but not glucose, for 10 wk indicate that the 2 sugars have differential effects on regional adipose deposition. However, the
increase of fasting glucose, insulin, and homeostasismodel assessment-insulin resistance at 2 wk and the lack of increase
of 24-h systemic FFA concentrations suggest that fructose decreases insulin sensitivity independently of visceral adiposity
and FFA. The lower postprandial glucose and insulin excursions in subjects consuming fructose and increased excursions
in those consuming glucose do not support a relationship between dietary glycemic index and the development of
dyslipidemia, decreased insulin sensitivity, or increased visceral adiposity. J. Nutr. 139: 1236S–1241S, 2009.
Introduction
Although there is convincing evidence that diets high in fructose
can produce obesity, insulin resistance/glucose intolerance, and
dyslipidemia in animals, direct experimental evidence that
sustained consumption of fructose promotes the development
of metabolic syndrome in humans has been much less well
documented (1–5). However, results from our recent study
comparing the metabolic effects of 10 wk of fructose and glucose
consumption demonstrate that a high-fructose diet induces
dyslipidemia, insulin resistance, and increased visceral adiposity
(6). The strength of the data, particularly with regards to the
effects on lipid metabolism, leads to the question of why results
from many earlier investigations of fructose consumption in
humans have been inconclusive. The purpose of this review is to
address this question, focusing on several aspects of study design
that are important when investigating the effects of fructose, and
likely many other dietary factors, on lipid and carbohydrate
metabolism. In addition, we will highlight some of the issues
raised by the results that we think should be considered in the
design and interpretation of future clinical research on the role
of fructose in the development of metabolic syndrome.
Overview of study design
The study was designed as a prospective, blinded diet interven-
tion with a 2-wk baseline period on a high-complex carbohy-
drate, moderate-fat diet and a 10-wk diet intervention phase
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(Table 1) during which overweight to obese (BMI 25–35) men
and women (43–70 y) consumed either fructose- or glucose-
sweetened beverages providing 25% of energy requirements
[calculated by the Mifflin equation (7)]. Metabolic inpatient
studies were performed during the baseline period and the final
2 wk of the intervention phase. During the inpatient baseline and
intervention periods, energy-balanced (weight-maintaining)
meals were provided (55% of energy as carbohydrate, 30%
fat, 15% protein), with the intervention meals being as identical
as possible to the baseline meals (55% complex carbohydrate)
with the exception that the carbohydrate energy was provided
30% as complex carbohydrate and 25% as fructose- or glucose-
sweetened beverages. During the first 8 wk of the intervention
period, the subjects resided in their own homes and were
provided with 3 servings/d of fructose- or glucose-sweetened
beverages that were consumed along with a self-selected ad
libitum (usual) diet.
A number of procedures were performed during the inpatient
baseline and intervention periods, including abdominal com-
puterized tomography scans for quantification of intra- and
extra-abdominal fat area, and oral glucose tolerance tests and
deuterated glucose disposal for assessment of insulin sensitivity.
In addition, 24-h blood collections, consisting of 36 samples
collected from 0800 to 0800 the following morning, were
performed during baseline and wk 2, 8, and 10 of intervention.
The baseline and intervention wk 10 collections were preceded
by 10 d of consumption of an energy-balanced (weight
maintaining) diet and the collections at intervention wk 2 and
8 were preceded by periods of ad libitum feeding. The purposes
of this combined inpatient/outpatient design were to compare
the effects of the high-fructose and -glucose diets under well-
controlled metabolic conditions (at baseline and intervention wk
10) and to also investigate the potentially additive or synergistic
interactions between the consumption of sugar-sweetened bev-
erages with components of the subjects’ typical diets consumed
ad libitum that might lead to greater effects on lipid metabolism
and insulin sensitivity/glucose tolerance (at intervention wk 2
and 8).
Postprandial blood sampling
There are aspects of the design of this study that we consider
critical to adequately assess the metabolic effects of sugar
consumption. Collection of blood samples during the postpran-
dial period is one of the most important. Bantle et al. (8) were
first to report that 24-h triglyceride (TG)3 postprandial profiles
increased in men after consuming a 6-wk diet providing 17%
energy as fructose compared with a diet providing 17% energy
from glucose; however, this difference was not apparent in
women. We subsequently reported pronounced and consistent
effects of both short-term (9,10) and long-term (6) fructose
consumption to increase TG area under the curve (AUC) during
14- or 24-h blood sampling in both men and women. In our
recent study, the 23-h TG AUC were increased by ~100% in
subjects consuming fructose and tended to be decreased in
subjects consuming glucose. However, despite the marked
increases in the 23-h TG AUC, fasting TG concentrations did
not increase after 2, 8, or 10 wk of fructose consumption (6).
This is not an entirely unexpected finding. We and other
investigators have reported that long-term consumption ($2
wk) of fructose at 20–25% of energy did not increase fasting TG
concentrations in older overweight women (11), in healthy male
and female subjects (12), in hyperinsulinemic female subjects
(13), in male and female patients with type 2 diabetes (14,15),
and in men with hypertriglyceridemia (16). In other studies,
however, consumption of fructose for $2 wk at 15–20% of
energy has been reported to increase fasting TG concentrations
in healthy (8,17–19) and hyperinsulinemic male subjects (19,20)
and in patients with hypertriglyceridemia and type 2 diabetes
(21). The reasons underlying these conflicting results are not
clear but are likely to be less important than the observation that
fasting TG concentrations are not a reliable indicator of
fructose-induced dyslipidemia. There is growing evidence link-
ing increased postprandial TG concentrations with a proathero-
genic state (22–27). This association may be mediated by the
remodeling of lipoproteins induced by postprandial hypertri-
glyceridemia (28–30). Accordingly, in addition to increased
concentrations of postprandial TG, the participants consuming
fructose in our recent study exhibited marked and significant
increases in fasting and postprandial apolipoprotein-B (apoB),
fasting small dense LDL (sdLDL), and postprandial remnant
lipoprotein concentrations (6). The observation that fasting TG
concentrations were unaffected in this setting contrasts with the
markedly increased postprandial TG concentrations and other
adverse changes of lipid parameters measured in these subjects
during fructose consumption. It also substantiates the growing
concern that standard clinical profiling, as well as many clinical
studies investigating lipid levels and cardiovascular disease risk,
do not include measurements of TG levels in the postprandial
state (25,31).
Sustained fructose exposure
We have observed prominent differences in the effects of fructose
consumption during short-term (24-h) compared with long-term
studies (+2 wk). These results have led us to conclude that long-
term studies are necessary to reliably determine the sustained
metabolic effects of fructose consumption. In 24-h studies, we
have consistently observed that consumption of fructose bever-
ages with each meal for 1 d results in increased fasting TG
concentrations of ~25% the following morning (9,10). As
discussed above, fasting TG concentrations were unchanged
TABLE 1 Study design
Study period Setting Duration Diet
Baseline Inpatient 2 wk Energy balance diet: 55% complex carbohydrate, 30% fat, 15% protein
Intervention Outpatient 8 wk Ad libitum usual diet and sugar-sweetened beverages providing 25%
of energy requirement
Intervention Inpatient 2 wk Energy balance diet: 25% sugar-sweetened beverage, 30% complex
carbohydrate, 30% fat, 15% protein
3 Abbreviations used: apoB, apolipoprotein-B; AUC, area under the curve; DNL,
de novo lipogenesis; GI, glycemic index; HFCS, high-fructose corn syrup; sdLDL,
small dense LDL; TG, triglyceride.
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during our previous (11) and recent long-term studies after 2, 8,
or 10 wk of fructose consumption (6). Another difference
between the effects of short-term and long-term exposure
to fructose-containing beverages is in the effects on plasma
apoB concentrations. In participants from our recent long-term
study, both fasting and postprandial apoB concentrations were
increased by ~25% after 2, 8, and 10 wk of fructose consump-
tion (6). However, in 24-h studies, consumption of fructose-
sweetened beverages with 3 meals resulted in significant decreases
of postprandial apoB concentrations (210% at 2200 h) com-
pared with fasting levels (9). This decrease is surprising given
it is observed concurrently with marked increases of postpran-
dial TG concentrations. Delineating the mechanism behind this
transitory decrease of apoB may provide new insight into the
regulation of VLDL production. Nonetheless, a more immediate
point is that the effects of acute exposure to dietary fructose
can be markedly different from those observed after sustained
fructose exposure. Long-term studies are also necessary for
identifying progressive effects of sustained fructose consump-
tion. An example is provided by the sdLDL results from our
recent study. Fasting sdLDL concentrations increased progres-
sively during fructose consumption: by 20% after 2 wk, 30%
after 8 wk, and 40% after 10 wk (6). Long-term studies with
both fasting and postprandial measurements are clearly required
to fully evaluate the metabolic effects of prolonged consumption
of fructose on lipid metabolism.
Positive energy balance
Participants in our recent study consumed sugar-sweetened
beverages (at 25% of weight-maintaining energy requirements)
along with their usual ad libitum diets during an 8-wk outpatient
period (Table 1). During this period, both groups were in positive
energy balance, gaining an average of ~1.4 kg (6). Clearly, the
adverse effects of fructose consumption on lipid metabolism and
insulin sensitivity cannot be explained solely by positive energy
balance or weight gain, because these effects were absent in the
participants who consumed glucose-sweetened beverages despite
a comparable amount of weight gain. However, this does not
preclude the possibility of an interaction of positive energy
balance and/or weight gain with fructose consumption resulting
in greater effects on lipid and carbohydratemetabolism than if the
subjects hadbeen studiedonly in a state of neutral energybalance.
It is possible that such an interactionmay have contributed to the
impairment of glucose tolerance and reduced insulin sensitivity in
the participants consuming fructose.
Insulin resistance
The participants consuming fructose exhibited increased fasting
glucose and insulin concentrations as well as an increase of the
homeostasis model assessment-insulin resistance. In addition,
increased glucose and insulin excursions during the oral glucose
tolerance test and decreased insulin sensitivity as assessed by
deuterated glucose disposal (32) were observed (6). In contrast,
it has been reported that the substitution of fructose at 18% of
the energy requirement to an energy-balanced, moderate-fat diet
in 7 young, normal-weight men for 4 wk increased fasting
glucose levels; however, other indices of insulin resistance, as
well as hepatic TG content, were unaffected (18). Study design
differences, including the amount (18 vs. 25% of energy
requirement) and duration (4 vs. 10 wk) of fructose exposure,
could contribute to the conflicting results. In addition, differ-
ences in the ages of the subjects (23 vs. 53 y) or in their baseline
insulin sensitivity (fasting insulin, 58 vs. 101 pmol/L) may have
rendered the participants in our study more susceptible to the
effects of fructose to induce insulin resistance.
Positive energy balance and insulin resistance
It is also likely that the 8-wk exposure to positive energy balance
contributed to the decrease of insulin sensitivity in the partic-
ipants consuming fructose. It has been proposed that hepatic TG
accumulation is a major mediator of hepatic insulin resistance
(33,34). TG accumulates in the liver when TG production
exceeds FFA oxidation and VLDL production and secretion
(35). We suggest that participants who consumed fructose and
excess energy from other foods concurrently may have produced
enough TG, via fructose-induced de novo lipogenesis (DNL), to
exceed the liver’s capacity for FFA oxidation and VLDL
production and secretion, thus resulting in increased liver TG
content and insulin resistance. Supporting this suggestion was
our observation that energy intake measured during the preced-
ing day was significantly correlated to the fructose-induced
increases of postprandial apoB and TG concentrations (6),
outcomes that are directly affected by increased hepatic lipid
availability (36). In contrast, in the study by Le et al. (18) in
which the 7 young men consumed fructose in the context of an
energy-balanced diet, DNL may have increased; however, in the
absence of positive energy balance, insufficient TG was pro-
duced to exceed FFA oxidation and VLDL production and
secretion. Thus, these subjects did not exhibit increases of liver
TG content or insulin resistance (18). It also follows that the
participants consuming glucose in our study in the setting of
positive energy balance did not produce sufficient TG to exceed
FFA oxidation and VLDL production and secretion, because the
glucose-sweetened beverages did not result in increased DNL. It
is possible that both increases of DNL and positive energy
balance are required to increase liver TG and thus promote the
development of insulin resistance in participants consuming
fructose, which may explain the differences between our results
(6) and those of Le and Tappy (18). Additional studies will be
required to further test the hypothesis that fructose-induced
DNL, in a setting of positive energy balance, induces insulin
resistance by increasing the intrahepatic TG pool.
Future clinical research on development of
metabolic syndrome
In addition to having potentially important public health
implications, we believe the results from our recent study can
influence the direction of future clinical research on development
of metabolic syndrome. The data regarding intra-abdominal fat
deposition, FFA levels, and glycemic exposure are of particular
interest.
Fructose and intra-abdominal fat deposition
As noted above, during the 8-wk outpatient period, when the
subjects in the study consumed their usual diets ad libitum along
with either fructose- or glucose-sweetened beverages at 25% of
energy requirements, the subjects gained an average of 1.4 kg.
Surprisingly, intra-abdominal fat area (measured by computer-
ized tomography) significantly increased in participants con-
suming fructose but was unchanged in participants consuming
glucose. In contrast, the extra-abdominal (subcutaneous) fat
area significantly increased in the participants consuming
glucose and not in those consuming fructose (6). These results
suggest that fructose consumption may specifically promote
lipid deposition in visceral adipose tissue. We observed increased
expression of the lipogenic genes stearoyl-CoA desaturase-1,
fatty acid desaturase 1, and fatty acid desaturase 2 in subcuta-
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neous gluteal fat of the participants who consumed glucose for
10 wk, whereas the expression of these genes was unchanged in
the participants consuming fructose (6). These data also suggest
differences in the effects of the fructose and glucose on regional
adipose deposition. The mechanism(s) underlying the differ-
ences are unclear but could involve the differential effects of the
2 sugars on postprandial exposure to TG and remnant lipopro-
teins. Votruba and Jensen (37) recently reviewed what is known
about regional differences in adipose tissue TG uptake and
concluded that the contribution of VLDL-TG uptake by
different depots to regional body fat distribution is unknown
and requires future study. The differential effects of fructose and
glucose on insulin sensitivity and/or glucose-induced postpran-
dial insulin excursions (discussed below) could also be involved.
Insulin has been demonstrated to increase lipoprotein lipase
expression in human subcutaneous compared with omental
adipose tissue ex vivo (38). Clearly, the effect of fructose
consumption to preferentially increase visceral adipose deposi-
tion compared with glucose consumption is an interesting
observation that warrants further mechanistic investigation.
Fructose and FFA
As discussed above, consumption of a diet high in fructose, but
not one high in free glucose, promoted dyslipidemia, insulin
resistance, and increased visceral adiposity (6). These results
suggest that this investigation and future such studies may lead
to a better understanding of the sequence of events leading to the
development of metabolic syndrome. The portal hypothesis of
insulin resistance (39) has been proposed as an explanation for
the association among central obesity and insulin resistance and
the pathogenesis of metabolic syndrome. Bergman et al. (40)
have recently concluded that FFA per se are among the most
important products of the visceral adipocyte contributing to
insulin resistance and hence metabolic syndrome and that the
anatomical position of the visceral adipose depot (i.e. portal
drainage to the liver) plays an important role in the pathogenesis
of metabolic syndrome. However, an interesting and potentially
important finding from our study is that fasting and 24-h
systemic FFA profiles were unchanged in participants consuming
fructose, whereas those consuming glucose had modest but
significantly increased 24-h circulating FFA concentrations (6).
Based on this observation and on the observation that fructose
consumption appears to impair insulin resistance in as few as
2 wk, we proposed that a high-fructose diet, which provides
substrate for DNL, can produce a lipid overload in the liver that
results in hepatic insulin resistance independently of increased
visceral adiposity and FFA levels (41). Additional studies are
necessary to further investigate the mechanism underlying
fructose-induced insulin resistance.
Glycemic exposure/glycemic index
The results from this study also illustrate some important
relationships between glycemic exposure and dyslipidemia,
cardiovascular disease risk, and insulin resistance. It has been
proposed that elevated postprandial glucose excursions may
increase the risk of cardiovascular disease even in nondi-
abetic persons (42). Glycemic index (GI) is used to categorize
carbohydrate-containing food by the 2-h blood glucose response
to a specified amount of the food relative to the response to an
isocaloric amount of pure glucose or white bread. High GI diets
have been associated with the development of cardiovascular
disease (43–46), insulin resistance (47), and type 2 diabetes
(48,49). However, there are also a number of conflicting reports
indicating that high GI diets are not associated with the
development of cardiovascular disease (50), insulin resistance
(51), or type 2 diabetes (52,53). The following reasons for these
inconsistent results have been suggested: 1) the 2-h glycemic
response to mixed meals may not reflect the chronic physiolog-
ical effects; 2) glycemic responses to the same meal can vary
considerably when consumed serially throughout the day and
there is also a large degree of interindividual variation; and 3)
the impact of protein and fat in the overall diet on the glycemic
response is the subject of debate (54).
Glycemic exposure and the effects of glucose and
fructose consumption
A further implication of our recent data is that dietary fructose
may be an important contributor to the inconsistent reported
effects of dietary GI on metabolic disease risk. The GI of fructose
is 23 compared with 100 for glucose and the calculated relative
GI of the baseline high-complex carbohydrate diet and the high-
glucose and high-fructose intervention diets consumed during
the 24-h blood collections in our study were 64, 83, and 38,
respectively (based on the glucose standard). As expected, the
glucose and insulin excursions (mean amplitude of the 3
postmeal glucose peaks) of the 3 diets paralleled the GI, with
exposure being highest with the glucose diet, intermediate with
the complex carbohydrate diet, and lowest with the fructose
diet. However, it was the participants who consumed the high-
fructose diet, the diet that had the lowest GI (GI = 38) and that
produced the least glycemic exposure, who developed a more
atherogenic lipoprotein profile, glucose intolerance, and de-
creased insulin sensitivity (6). In contrast, when participants
substituted the high-glucose diet (GI = 83) for the complex
carbohydrate diet (GI = 64), postprandial plasma glucose and
insulin excursions increased substantially; however, postpran-
dial TG exposure, apoB, sdLDL, remnant lipoproteins, and
insulin sensitivity remained unchanged (6). Thus, these results
do not support the hypothesis that elevated postprandial glucose
and/or insulin excursions contribute to dyslipidemia, insulin
resistance, an increased risk of cardiovascular disease, or type
2 diabetes in older overweight/obese men and women. These
results also demonstrate that studies investigating the relation-
ship of dietary carbohydrates to the development of metabolic
diseases must carefully distinguish between and accurately
determine dietary glucose and fructose contents. It has recently
been suggested that a fructose index may be more relevant with
respect to cardiovascular disease risk than the GI (55).
Summary and conclusions
In summary, studies of the metabolic effects of dietary fructose
should include postprandial sampling (24 h when possible) and
an intervention of sufficient length to evaluate the impact on
lipid metabolism and insulin sensitivity. The effects of whether
the participants are in a neutral or positive energy balance needs
to be considered and both male and female participants should
be studied, because there appear to be important gender
differences in the metabolic responses to fructose consumption.
While our recent investigation generated important new data
regarding the long-term effects of consuming glucose and
fructose-sweetened beverages, there are a number of additional
questions to be addressed: 1) What are the effects of consuming
fructose at 25% of energy requirements to promote dyslipidemia
and to decrease glucose tolerance/insulin sensitivity in different
populations, including younger normal-weight adults compared
with overweight/obese adults?; 2) Are these effects present in
normal-weight or overweight/obese participants when lower
(10–15% of energy) or intermediate (15–20% of energy)
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amounts of fructose are consumed?; and 3) What are the
metabolic effects of consuming high-fructose corn syrup (HFCS)
or sucrose, the predominant sweeteners in the U.S. food supply,
which are a mixture of glucose and fructose (HFCS contains 42–
55% fructose and sucrose contains 50% fructose) at low,
intermediate, and high levels?
We are currently conducting a dose-response study of the
effects of consuming both fructose andHFCS at 3 different levels
on lipid metabolism, glucose tolerance/insulin sensitivity, and
hepatic TG content in normal-weight insulin-sensitive, and
overweight/obese insulin-resistant men and women under the
age of 40 y. In conducting these studies, we expect to obtain the
data needed to address the questions raised above. Also needed
are studies of the metabolic effects of fructose and HFCS/sucrose
consumption in pediatric populations, including both children
and adolescents.
Other articles in this supplement include references (56–65).
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